Gastrointestinal Stromal Tumor

In gastrointestinal-stroma-tumors (GIST) as well. (@hennig_f)

🎙️ Tune in as @LLuxner interviews @JasonSicklick an expert on #GastrointestinalStromalTumor (#GIST). Dr. Sicklick’s laboratory focuses on the molecular mechanisms of GIST development and drug resistance in advanced GIST. #GISTAwarenessDay Listen here ➡️ https://t.co/KGRTS0HhoI (@RareDisease_Adv)

July 13 is #GIST Awareness Day. #gastrointestinal #stromal #tumor. Read my story about this rare #cancer in today's @RareDisease_Adv. @RareDiseases @Liferaftgroup @GlobalGenes @PAWSGIST @jasonsicklick @GISTCancerUK @GISTSupportUK @Sarcoma_UK @srothschild https://t.co/YVwPV373BW (@LLuxner)

@richardriedelmd of @DukeCancer reviews data on tyrosine kinase inhibitor dose escalation in patients with advanced gastrointestinal stromal tumors. https://t.co/OtsncuEEkT #twittermed #medtwitter #mdtwitter #onctwitter #oncology #oncologist #gist #cancerresearch #cancercare (@eponcology)

@richardriedelmd of @DukeCancer reviews data on tyrosine kinase inhibitor dose escalation in patients with advanced gastrointestinal stromal tumors. https://t.co/ROy8lMkDlV #twittermed #medtwitter #mdtwitter #onctwitter #oncology #oncologist #gist #cancerresearch #cancercare (@ExpertsMedicine)

We've heard the #TumorBoardTuesday community and we're bringing you our FIRST #Sarcoma case this week! Join us 06/20/23 at 8pm when @SteveBialickDO @GinaDAmatoMD1 take us through TKI selection in GI stromal tumors #GIST as a prelude into July's #SarcomaAwarenessMonth! (@TumorBoardTues)

KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial https://t.co/3dxDyIp0ei (@PestanaRC)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor #gist #sarcoma https://t.co/yyK74E0QWa (@JTrentMDPhD)

#CAP22 Day 2 Poster session: "Quadruple negative NTRK-rearranged gastrointestinal stromal tumor of the esophagus" @AKE_Path @OhioStatePath #GIPath #PathTwitter (@BinduChalla1)

We evaluated Fibroblast Growth Factor Receptor inhibitors in our xenograft models of gastrointestinal stromal tumor. Some efficacy, unlikely a game changer, and again no added value when combining with imatinib. See Schöffski et al., doi: 10.3390/biomedicines10051135 (@schoffski)

👍 The combination of imatinib and binimetinib is effective w/ manageable toxicity in frontline treatment of #GastrointestinalStromalTumor ➡️ https://t.co/Fosnp4H7SX @WTapMD #GIST #JCO #scmsm (@JCO_ASCO)

KIT+ MEK inhibition in GIST ➡️Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor ⭐️The best ORR was 69.0% @WTapMD @JTrentMDPhD @JCO_ASCO https://t.co/4EKyGH0TsZ (@VivekSubbiah)

Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor #GIST harboring heterogenous KIT/PDGFRA mutations ⁦@seppobauer⁩ ⁦@schoffski⁩ ⁦@jeanyvesblay⁩ ⁦@GinaDAmatoMD1⁩ ⁦@SylvesterCancer⁩ https://t.co/rwLy6Gh01X (@JTrentMDPhD)

.@JTrentMDPhD, MD, PhD, @SylvesterCancer discusses the role of avapritinib in PDGFRA exon 18–positive gastrointestinal stromal tumor. #scmsm https://t.co/IL6jMnwHsI (@OncLive)

Ripretinib demonstrated clinically meaningful activity in patients with fourth-line or later advanced gastrointestinal stromal tumor and several, heterogeneous genetic subsets of KIT/PDGFRA mutations. @schoffski @KU_Leuven @ctosociety #CTOS2020 #scmsm https://t.co/rSSRzRCj66 (@OncLive)

AZD3229 is potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors. @AstraZeneca https://t.co/mlGQsX6ipS (@Intestinal_Cell)